Adjuvant Treatment With Interleukin-2- and Interferon-Alpha2a-Based Chemoimmunotherapy in Renal Cell Carcinoma Post Tumour Nephrectomy: Results of a Prospectively Randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Atzpodien, Jens; Schmitt, Eberhard; U, Gertenbach; Fornara, Paolo; Heynemann, H.; Maskow, Arndt; Ecke, M; Wöltjen, H.-H.; Jentsch, Holger; Wieland, W.F.; Wandert, T.; Reitz, Martina

doi:10.1016/s0022-5347(05)00090-x

Cited by 8 publications

(13 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of cytokine therapy in the adjuvant setting to reduce the risk of distant failure following local treatment with curative intent was not found to be beneficial in patients with clear cell RCC [76-78]. Adjuvant targeted therapies are now being evaluated with trials in the United States, Europe and Asia [9, 79].…”

Section: Cytoreductive Nephrectomy Neoadjuvant and Adjuvant Therapymentioning

confidence: 99%

Targeted therapies for non-clear renal cell carcinoma

et al. 2010

View full text Add to dashboard Cite

The treatment of advanced and metastatic kidney cancer has been revolutionized by the development of targeted systemic therapies. Despite the growing number of available agents approved for use against clear cell renal cell carcinoma, patients with non-clear histologies, constituting approximately 1 in 4 cases of kidney cancer, have not received the same attention. The majority of clinical trials testing novel targeted therapies have excluded non-clear subtypes, providing limited therapeutic options for patients with these diagnoses and their oncologists. This review will focus on the use of targeted therapies against the non-clear histologic subtypes of renal cell carcinoma: papillary I and II, chromophobe, and collecting duct. The unique genetic and molecular profiles of each distinct non-clear kidney cancer subtype will be described, as these differences are integral to the development and effectiveness of the novel agents used to treat them. Trials focusing on non-clear kidney cancer, or those that treated clear cell tumors along with significant numbers of non-clear subtypes, will be discussed. The role of cytoreductive nephrectomy and the use of neoadjuvant and adjuvant targeted therapy will be reviewed. Lastly, areas of future research will be highlighted.

show abstract

Section: Cytoreductive Nephrectomy Neoadjuvant and Adjuvant Therapymentioning

confidence: 99%

Targeted therapies for non-clear renal cell carcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Five-year survival rate is less than 5% with a high risk of disease recurrence with rates ranging from 50–85% depending on tumour state and lymph node involvement 1. Despite advances in adjuvant systemic treatments for RCC, surgical resection continues to be the best option for improved long-term survival in selected patients with RCC and liver involvement by contiguity 2 3.…”

Section: Discussionmentioning

confidence: 99%

Partial nephrectomy and enbloc liver resection using a bipolar radiofrequency device for renal cell carcinoma invading the liver

Pitchaimuthu

Pai²

2010

Case Reports

View full text Add to dashboard Cite

SummaryA 66-year-old man presented with right-sided abdominal pain. Ultrasound, CT and MRI scans showed a right renal mass arising from the upper pole with direct involvement of the right lobe of the liver. Biopsy confirmed renal cell carcinoma. After Multi Disciplinary Team (MDT) discussion, right partial nephrectomy with enbloc resection of segments VI and VII of the liver was performed with the help of intraoperative ultrasound scan and the Habib 4X bipolar radiofrequency device. Apart from symptomatic collection, which was drained radiologically, the patient made a good recovery. The patient developed recurrence at the resection margin but is in remission following chemotherapy at 12 months. BACKGROUND

show abstract

“…In kontrollierten klinischen Studien ließ sich mit zytokinbasierten adjuvanten Therapien beim Nierenzellkarzinom kein Effekt nachweisen [59]. …”

Section: Adjuvante Therapieunclassified

Interdisziplinäre Empfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms

et al. 2014

View full text Add to dashboard Cite

Zusammenfassung Patienten mit metastasiertem Nierenzellkarzinom (mRCC) haben eine lebensbegrenzende Prognose. Die Zielsetzung der Therapie ist daher in der Regel palliativ. Dennoch konnten in den letzten Jahren deutliche Fortschritte erreicht werden. Die Immuntherapie mit Zytokinen in der palliativen Situation ist zunehmend durch neue zielgerichtete Substanzen abgel?st worden. Sunitinib, die Kombination Bevacizumab+Interferon-alpha, Pazopanib sowie Temsirolimus sind f?r die Erstlinie beim mRCC zugelassen. Sunitinib und Pazopanib haben eine Zulassung auch f?r die Zweitlinientherapie ? f?r Pazopanib ist diese auf den Einsatz nach Zytokinen beschr?nkt. Everolimus (nach TKI-Therapie) und Sorafenib (nach Zytokintherapie) sind weitere Substanzen, die in der Zweitlinientherapie zur Verf?gung stehen. Neu zugelassen wurde Axitinib, es kann nach Versagen einer Sunitinib- oder Zytokintherapie eingesetzt werden. Zur Frage nach der optimalen Sequenz gibt es erste Studienergebnisse aus einer Phase III Studie. Welche Kriterien einer Therapieentscheidung zugrundgelegt werden sollten, wurde im Rahmen eines Expertenmeetings unter Ber?cksichtigung der 2012 publizierten Daten diskutiert. Wie in den Vorjahren war es auch diesmal das Ziel des interdisziplin?ren Expertengespr?chs, gemeinsame Therapieempfehlungen auf Basis der publizierten Daten und der eigenen klinischen Erfahrung zu erarbeiten und f?r den Praxisalltag abzuleiten. Das interdisziplin?re Board kn?pfte an Therapieempfehlungen aus dem Jahr 2012 an 1. Die Publikation fasst die Ergebnisse der Diskussion zusammen und enth?lt einen aktuellen Therapiealgorithmus.

show abstract

Adjuvant Treatment With Interleukin-2- and Interferon-Alpha2a-Based Chemoimmunotherapy in Renal Cell Carcinoma Post Tumour Nephrectomy: Results of a Prospectively Randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Cited by 8 publications

References 1 publication

Targeted therapies for non-clear renal cell carcinoma

Targeted therapies for non-clear renal cell carcinoma

Partial nephrectomy and enbloc liver resection using a bipolar radiofrequency device for renal cell carcinoma invading the liver

Interdisziplinäre Empfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms

Contact Info

Product

Resources

About